Snoretox

Name

Snoretox

Website

https://snoretox.com

Company type

Private

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Sleep Neurology (Neurologic Sleep Disorders) (HLAKAIAJ)

Keywords

• Toxin-based therapeutics
• Muscle tone disorders
• Sleep apnea therapeutics
• Neuromuscular biopharmaceuticals
• Biologic drug development

Headquarters

HQ city

Bundoora

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Snoretox develops toxin-based therapeutics targeting muscle tone disorders and sleep apnea. The company operates as a small Australian biotechnology firm working on biologic drug candidates intended to address neuromuscular dysfunction underlying sleep-disordered breathing and related tone abnormalities. No specific product candidates, clinical stage, or formulation details are publicly disclosed.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• Revance Therapeutics: Commercial-stage biotechnology company developing toxin-based therapeutics (DAXXIFY/daxibotulinumtoxinA) for aesthetic and therapeutic indications. Closest direct peer on the toxin-platform axis, demonstrating the commercial viability and regulatory pathway Snoretox would need to follow.
• Galderma: Dermatology-focused pharmaceutical company with leading botulinum toxin franchises. Comparable on the toxin-therapeutic development, manufacturing, and commercial infrastructure axis, though primarily active in aesthetic/dermatology rather than sleep indications.
• Apnimed: Clinical-stage pharmaceutical company developing oral pharmacotherapies for obstructive sleep apnea. Direct peer in the sleep apnea drug development race, pursuing a different (pill-based) mechanism but targeting the same CPAP-intolerant population Snoretox aims to serve.

Broad incumbents

• Inspire Medical Systems: Established medical device company marketing hypoglossal nerve stimulation therapy for CPAP-intolerant obstructive sleep apnea. Competes for the same patient segment Snoretox would target, but via an implanted neurostimulation device rather than a pharmaceutical.
• Fisher & Paykel Healthcare: Global manufacturer of CPAP devices, humidification systems, and respiratory care products. Represents the device-side standard of care that any new OSA pharmaceutical must displace or complement, and a key competitor for clinical and payer mindshare.
• Jazz Pharmaceuticals: Specialty pharmaceutical company with a portfolio of CNS/sleep medicines (Xywav, Sunosi) addressing narcolepsy, idiopathic hypersomnia, and sleep-related breathing disorders. A relevant large-cap reference point for commercializing sleep-disorder therapeutics.
• ResMed: Global leader in CPAP devices and digital health solutions for sleep apnea and other respiratory conditions. Represents the entrenched first-line standard of care Snoretox's therapeutic would need to differentiate against.
• Ipsen: Global specialty biopharmaceutical company with a major botulinum toxin franchise (Dysport) across therapeutic and aesthetic indications. A relevant incumbent on the toxin-therapeutic manufacturing, regulatory, and commercialization axis.

Emerging players

• Theravance Biopharma: Specialty biopharmaceutical company developing therapeutics for respiratory and neurologic conditions. Comparable as a small-cap specialty pharma pursuing differentiated mechanisms in respiratory/neurology adjacencies to sleep apnea.
• Avadel Pharmaceuticals: Specialty pharmaceutical company focused on sleep-disorder medicines (notably Lumryz for narcolepsy). Comparable as a smaller commercial-stage player navigating sleep-specialty pharma commercialization, though in a different sleep indication.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/snoretox-pty-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Snoretox